Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The new findings are an important first step in moving toward using even less radiation to treat high-risk pediatric Hodgkin lymphoma.
Adcetris plus chemotherapy approved under pilot program that aims to speed drug review and approval.
Approval of brentuximab vedotin was based on a study showing improved progression-free survival.
Approval was based on a phase 3, randomized, open-label, multicenter clinical trial (ALCANZA).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.